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Summary.-We have studied the cytotoxicity of bleomycin (4-10 u/kg/day for 6 days)
given by continuous i.p. infusion (using an osmotic minipump) compared to daily i.p.
bolus administration, against P388 leukaemic spleen colony-forming-units(LCFU-S).
Continuous i.p. bleomycin at 8 u/kg/day caused a 0-5 log greater reduction of LCFU-S
than did an identical dose given by intermittent bolus administration. The infusion
minipump provided constant bleomycin plasma levels of 0-62 +003 mu/ml and a
total plasma AUC (area under the plasma decay curve) of 89-0 mu.h/mlfor 6 days at
8 u/kg/day. Intermittent bolus bleomycin at 8 u.kg,/day had a terminal-phase plasma
t1/2 of 15 min and a total 6-day plasma AUC of 90 8mu.h/ml. These pharmacokinetic
data validate the osmotic minipump as a constant drug-delivery system, and suggest
that the two administration schedules resulted in equal total bleomycin dosages.
Although high peak bleomycin plasma levels (i.e. 32 mu/ml) were achieved with the
intermittent bolus administration, continuous-infusion bleomycin's greater inhibi-
tion of LCFU-S was probably related to the drug's schedule-dependent cell-killing
characteristics. The results of this study provide further rationale for the continuing
use of infusion bleomycin schedules in cancer patients.
BLEOMYCIN has proven effectiveness
against several human cancers when
administered either intermittently (i.v.,
i.m., s.c. or i.p.) or by continuous infusion
(Prestayko & Crooke, 1979; Alberts et al.,
1979). There is some evidence that con-
tinuous i.v. infusion (C.i.v.) vs intermittent
i.v. push (I.i.v.) bleomycin (when com-
bined with mitomycin C and vincristine)
is associated with similar response rates
and less systemic toxicity in patients with
squamous-cell cancer of the cervix (Baker
et al., 1978). More recently Sikic et al.
(1978) have shown that continuous s.c.
(C.s.c.) bleomycin as compared to inter-
mittent s.c. (J.s.c.) bleomycin caused
longer survival and slower tumour growth
rates and pulmonary toxicity in mice
bearing Lewis lung carcinoma (Sikic et al.,
1978). We have studied the effect of
continuous i.p. (C.i.p.) vs intermittent i.p.
(I.i.p.) bleomycin against mouse leukaemia
spleen colony growth, and have correlated
the enhanced antileukaemic activity of
C.i.p. with its more favourable plasma
pharmacokinetics (Peng et al., 1979).
MATERIALS AND METHODS
Mice.-6-8-week-old male DBA/2 mice
weighing 20-25 g were purchased from the
Jackson Laboratory, Bar Harbor, Maine.
They were maintained on normal laboratory
chow and acid water ad. lib.
Mouse leukaemia.-P388 lymphocytic leu-
kaemia was supplied by Dr Daniel Griswold,
Southern Research Institute, Birmingham,
Alabama, and serially transplanted as ain
ascites tumour at weekly intervals (106 cells
every 7 days in McCoy's 5a medium. Gibco,
Grant Island, NY).
Spleen colony assay.-The mouse spleen-
colony assay system (Alberts & Wetters,
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1976) was used to determine the efficacy of
C.i.p. vs Li.p. bleomycin.
On Day 0, 106 P388 ascites tumour cells
were injected i.v. into groups of5 male DBA/2
mice. For the Li.p. group, bleomycin (2-10
u/kg/day) was administered i.p. daily from
Day 1 to Day 6. For the C.i.p. group, the
Alzet osmotic minipump was implanted on
Day 1 and was left in place for 6 days. To
implant the pump, the animal was first
anaesthetized with pentobarbital, a small
incision was made in the abdomen, the mini-
pump filled with bleomycin (2-10 u/kg/day)
was inserted i.p. and the incision was closed
with surgical clips. Ill addition to an un-
treated control group, 5 animals were
implanted with minipumps containing 0.900
NaCl.
Seven days after cell injection, the mice of
the untreated control and treated groups were
killed, femurs isolated, and marrow cells
washed out with McCoy's 5a medium. Appro-
priate dilutions of the leukaemic femoral
marrow cells were injected i.v. into groups of
10 DBA/2 mice. Eight days later, the recipient
mice were killed, spleens removed and fixed
in Bouin's solution. The number of surface
nacroscopic, leukaemic colony-forming units
(LCFU-S) were counted with a dissecting
microscope, and the fraction of surviving
LCFU per femur determined.
Pharmacokinetic studies.-On Day 0, 106
P388 ascites cells were injected i.v. into
groups of 30 DBA/2 mice. C.i.p. and Li.p.
bleomycin treatments were carried out as
previously described. For the C.i.p. group,
blood samples from at least 3 mice were col-
lected in heparinized tubes by heart puncture
every day for 6 days. For the Li.p. group,
blood samples were collected at 5, 15, 30, 45,
60, and 120 min after the administration of
bleomycin on Day 5. At least 3 mice were
killed at each sampling time.
Blood samples were centrifuged at 2,000
rev/min and 4°C for 10 min and the plasmas
separated and immediately stored at -20°C.
The bleomycin concentrations were deter-
mined using the antiserum and radio-
immunoassay technique developed by
Broughton & Strong (1976). Bleomycin
stability in the Alzet minipump was deter-
mined at 37°C for 7 days in saline.
Data analysis-Statistical analysis of the
differences betwNeen LCFU dose-response
(i.e., drug dose vs fraction of CFU surviving
per femur) curves for the two different treat-
ments used the analysis ofcovariance method
(Snedecor & Cochran, 1979).
Bleomycin plasma concentrations vs time
data were fitted to a single exponential
equation using a nonlinear regressing com-
puter programme (Metzler, 1969). Bleomycin
plasma half-lives and areas under the plasma
disappearance curves (AUC) were calculated
as previously described (Alberts et al., 1978).
RESULTS
Bleomycin in 0 9%0 NaCi had 100%
stability inside the osmotic minipumps for
at least 6 days at 37°C. We were therefore
able to use these minipumps to deliver a
constant infusion of bleomycin for 6 days.
Fig. 1 shows bleomycin dose-response
curves against LCFU. C.i.p. bleomycin
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FIG. 1. Bleomycin dose-response curves
against LCFU-S. The upper curve (A)
represents the inhibition of LCFU-S by
daily i.p. bolus injections of bleomycin,
whereas the lower curve (*) represents
inhibition of LCFU-S by continuous i.p.
infusion ofbleomycin.
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FIG. 2. Plasma disappearance of bleomycin
(8 u/kg/day) after continuous i.p. infusion
(-* ) vs internittemt i.p. bolus ( O )
adlministration in adult male DBA/2 mice.
Data points represent measured bleomycin
concentrations by radioimmunoassay in
pooled plasma samples from groups of 3
mice. I)otted lines are simulations of inter-
mittent i.p. bolus bleomycin data obtainedl
on Day 5.
caused an approximately 0 5 log greater
reduction of LCFU than did I.i.p. bleo-
mycin at doses of6-10 u/kg/day (P < 001).
The minipump provided constant bleo-
mycin plasma levels of 062 + 0 03 mu/ml
and a total AUC of 89-0 mu.h/ml for
6 days at 8 u/kg/day (Fig. 2), whereas
intermittent bolus bleomycin (8 u/kg/day)
had a peak plasma level of 32 mu/ml (at
5 min), a terminal-phase plasma t1/2 of
1]5 min and a total 6-day AUC of 908
mu.h/ml.
D1ISCUSSION
We have shown that C.i.p. bleomycin
caused a statistically greater inhibition of
LCFU-S thandidI.i.p. bleomycin atseveral
points along the dose-response curve.
These data and those of Sikic et al. (1978)
showing C.s.c. bleomycin to be superior to
I.s.c. bleomycin against Lewis lung car-
cinoma (Sikic et al., 1978) and to have less
pulmonary toxicity (i.e., decreased content
of lung collagen) strongly recommend
continuous infusion as the route of choice
for bleomycin administration. The study
of Baker et al. (1978) in patients witl
squamous-cell carcinoma of the cervix
has shown that bleomycin given by C.i.v.
along with mitomycin C and vincristine
had as much antitumour activity and less
systemic toxicity than when the drug was
given Li.v. along wvith similar doses of the
other 2 anticancer agents (Peng et al.,
1979).
Bleomycin appears to possess cell-cycle
specificity in its antitumour effects (Bar-
ranco, 1979). Like cytosine arabinoside
(Skipper et al., 1967; Mellett, 1972) and
other cell-cycle-specific agents, it may be
necessary to maintain a minimal cytotoxic
concentration of bleomycin while the
tumour cell is traversing the S phase of
the cell cycle in order to optimize cell kill.
Our plasma disappearance data for bleo-
mycin after C.i.p. administration shows
that drug concentrations of greater than
0 6 mu/ml plasma are maintained for
about 6 days. This is in contrast to the
short periods (about 92 min) during which
bleomycin plasma concentrations remain
above 0-6 mu/ml after Li.p. administra-
tion. The improved tumour-cell kill asso-
ciated with C.i.p. administration in this
study and C.s.c. in the study of Sikic
et al. (1978) can probably be explained by
bleomycin's more favourable plasma
kinetics after continuous infusion.
Future clinical-research studies using
bleomycin in the treatment of the lym-
phomas and testicular, head and neck and
lung cancers shouldbe designed to evaluate
the efficacy ofthe C.i.v. route. Using C.i.v.
bleomycin it may be possible to maintain
or improve on Li.v. bleomycin's anti-
tumour activity while decreasing its pul-
monary toxicity.
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